Patient access to new cancer treatments — an uncertain and fragile process

HemOnc Today, August 10, 2019
John Sweetenham, MD
As Tom Brokaw eloquently stated, uncertainty is at the heart of the cancer experience for our patients. It impacts many aspects of their lives, from…
Cover Story

BCG: a real-world example of health care rationing

HemOnc Today, August 10, 2019
Bacillus Calmette-Guérin, or BCG, is highly effective at treating and preventing recurrence of early-stage bladder cancer. BCG is a strain of…

Are there feasible alternatives to BCG for the effective treatment of bladder cancer?

HemOnc Today, August 10, 2019
POINT The BCG shortage has caused significant concern among both patients and providers as they consider their options for the treatment of…

Research initiative aims to better understand link between immunotherapy, type 1 diabetes

August 7, 2019
The Parker Institute for Cancer Immunotherapy, in collaboration with the Juvenile Diabetes Research Foundation and Helmsley Charitable Trust, have…
Trend Watch

CMS increases CAR T reimbursement by 15%

August 5, 2019
CMS has finalized its plan to increase its new technology add-on payment to 65% of the total cost of chimeric antigen T-cell therapies. The payment…

A new love affair — but will you respect me in the morning?

HemOnc Today, July 25, 2019
Derek Raghavan, MD, PhD
We have known for more than 50 years that immunotherapy is active against noninvasive bladder cancer, dating from the paradigm-altering work of…
Cover Story

Aggressive end-of-life care: A disservice to patients

HemOnc Today, July 25, 2019
The availability of more effective and less toxic anticancer agents has made it increasingly difficult for clinicians to discern when to discontinue…

NCCN Releases Inaugural Pediatric ALL Clinical Practice Guidelines

Cell Therapy Next, July 2019
The National Comprehensive Cancer Network recently released its first clinical practice guidelines for children with acute lymphoblastic leukemia…
Cover Story

Driving Killer CARs into Cancer

Cell Therapy Next, July 2019
Automobile pioneer Henry Ford once said of his best-selling Model T, “Any customer can have a car painted any color that he wants so long as…
Meeting News

Nonengineered T cells may be ‘clinically meaningful’ for pancreatic cancer

July 19, 2019
More than half of patients with pancreatic adenocarcinoma showed clinical responses when treated with an investigational multiantigen-specific T-cell…